Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH)
By O. Koç, J. Day, M. Nieder, Stanton L. Gerson, H. Lazarus, W. Krivit. Bone Marrow Transplantation, 2002
685 citations recorded by the source corpus.
Subfields: Genetics, Physiology, Psychiatry and Mental health
View Paper: https://www.semanticscholar.org/paper/0a43471b93bec22d0146ad96cceab999e1558ce0
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Physiology
In Psychiatry and Mental health
Citations in the corpus
- Safety of Cell Therapy with Mesenchymal Stromal Cells (SafeCell): A Systematic Review and Meta-Analysis of Clinical Trials (2012, methodology): “Tumour/malignancy (relapse) 12/46 GVHD (acute) 23/46 GVHD (chronic) 22/46 Koç et al, 2002 [22] Infusional toxicity (phlebitis) 1/11 Fever (transient) 4/11 Safety of Adult Stem Cells”
- Mesenchymal stem cells and their potential as cardiac therapeutics. (2004, background): “The hMSCs, with their attributes of (1) ease of isolation, (2) high expansion potential, (3) genetic stability, (4) reproducible attributes from isolate to isolate, (5) reproducible characteristics in widely dispersed laboratories, (6) compatibility with tissue engineering principles, and (7) potent”
- Mesenchymal stem cells avoid allogeneic rejection (2005, background): “Koc et al, showed no evidence of alloreactive T cells and no incidence of graft v host disease when allogeneic MSC were infused into patients with Hurler's syndrome or metachromatic leukodystrophy[16].”
- Comparative characteristics of mesenchymal stem cells from human bone marrow, adipose tissue, and umbilical cord blood. (2005, background): “Due to their accessibility, expandability, and multipotentiality, MSC hold promise for clinical applications [27–37].”
- Intravenous hMSCs Improve Myocardial Infarction in Mice because Cells Embolized in Lung Are Activated to Secrete the Anti-inflammatory Protein TSG-6 (2009, methodology): “…animal models and in clinical trials, the cells 54 Cell Stem Cell 5, 54–63, July 2, 2009 ª2009 Elsevier Inc. were intravenously (i.v.) infused (Pereira et al., 1998; Horwitz et al., 1999; Akiyama et al., 2002; Koc et al., 2002; Nomura et al., 2005; Le Blanc et al., 2007; Wu et al., 2008).”
- Mesenchymal stem cells: mechanisms of inflammation. (2011, methodology): “These experiments were followed by studies of patients with inborn errors of metabolism, such as metachromatic leukodystrophy and Hurler syndrome, who received allogeneic MSCs without adverse effects and showed some improvement in nerve-conduction velocity but not in overall clinical status (79, 80)”